In a patient with an amikacin‑susceptible Acinetobacter baumannii urinary infection who is not responding and has developed a new fever, should we discontinue amikacin and switch to colistin, or continue amikacin and add colistin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Switch to Colistin Monotherapy - Not Recommended

In a patient with amikacin-susceptible Acinetobacter baumannii urinary tract infection who is failing therapy with new fever, you should ADD colistin to amikacin rather than switching to colistin monotherapy. The organism remains susceptible to amikacin, and combination therapy offers superior microbiological eradication while preventing resistance emergence.

Rationale for Combination Therapy

Amikacin Remains Appropriate for UTI

The FDA label explicitly states that amikacin is indicated for infections caused by susceptible Acinetobacter species, and "a dose of 250 mg twice daily may be used" specifically for uncomplicated urinary tract infections 1. Since your isolate is amikacin-susceptible, there is no microbiological justification to discontinue it.

Colistin Combination Superior to Monotherapy

While recent high-quality RCTs show no mortality benefit for colistin-carbapenem combinations in severe CRAB infections 2, the evidence specifically demonstrates:

  • Microbiological eradication is significantly superior with combination therapy (OR: 1.88,95% CI = 1.13-3.12, p = 0.01) compared to colistin monotherapy 3
  • No difference in mortality or nephrotoxicity between monotherapy and combination approaches 3
  • The colistin-amikacin combination is particularly effective at eradicating persister cells, especially when colistin is given first followed by amikacin 4

Prevention of Resistance Development

Critical evidence shows that:

  • Colistin monotherapy at high concentrations fails to prevent colistin dependence in A. baumannii 5
  • Combinations of colistin with amikacin at subinhibitory concentrations successfully eradicate strains by inhibiting colistin dependence development 5
  • Sequential exposure (colistin then amikacin) completely eliminated persister cells within 6 hours, while reverse order left 0.016% persisters remaining 4

Clinical Algorithm

Step 1: Verify Susceptibility

  • Confirm amikacin susceptibility remains valid
  • Check colistin MIC if available (target ≤2 mg/L)
  • Rule out heteroresistance if clinical suspicion exists 6

Step 2: Add Colistin to Existing Amikacin

Colistin dosing for UTI:

  • Loading dose: 5 mg CBA/kg IV 7
  • Maintenance: 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h 7
  • Monitor renal function closely given nephrotoxicity risk 7

Continue amikacin:

  • 250 mg IV q12h for UTI 1
  • Monitor peak levels (target <35 mcg/mL) and trough (<10 mcg/mL) 1

Step 3: Reassess at 48-72 Hours

  • Clinical response (fever resolution, symptom improvement)
  • Repeat urine culture to document microbiological clearance
  • If no response by 3-5 days, consider source control issues or alternative resistance mechanisms 1

Important Caveats

Nephrotoxicity Risk

Both agents carry nephrotoxicity risk. The combination does not increase nephrotoxicity compared to colistin alone 3, but requires:

  • Daily creatinine monitoring 7
  • Dose adjustment for renal impairment 1
  • Adequate hydration 1

Colistin Limitations in Urine

Colistin achieves variable urinary concentrations. However, for systemic manifestations (fever, potential bacteremia from UTI source), systemic colistin levels are relevant. The combination approach addresses both urinary and potential systemic infection.

Duration of Therapy

  • 5-7 days for complicated UTI 7
  • Extend to 10-14 days only if bacteremia documented 7
  • Reassess need for continued therapy beyond 10 days with repeat cultures and clinical assessment 1

Why Not Switch to Colistin Alone?

Switching to colistin monotherapy would:

  1. Abandon an agent to which the organism is susceptible
  2. Reduce microbiological eradication rates 3
  3. Increase risk of colistin resistance emergence 5
  4. Provide no mortality or clinical cure advantage over combination 3, 8

The 2022 ESCMID guidelines acknowledge that while colistin-carbapenem combinations show no benefit for severe CRAB infections 2, this applies to carbapenem-resistant isolates. Your scenario involves an amikacin-susceptible organism where maintaining susceptible agent coverage is standard antimicrobial stewardship practice.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.